![[PDF]](/pb-assets/Icons/adobe-pdf-icon-1498649896243.png){kind=icon}
Abstract
Autism Spectrum Disorders (ASD) are diagnosed in early childhood and include Autism, Asperger's disorder and Pervasive neurodevelopmental disorder - not otherwise specified (PDD-NOS, or atypical autism). ASD are associated with varying degrees of dysfunctional communication and social skills, repetitive and stereotypic behaviors, as well as attention and learning disabilities. Most ASD patients also have food intolerance and other allergic symptomatology indicative of mast cell activation. The number of ASD cases have increased over the last decade to 1/100, but there is no definite pathogenesis or curative therapy. We report that the apparent prevalence of ASD in patients with mastocytosis, a rare disease occuring in 1/4,000 children and characterized by an increased number of hypersensitive mast cells in many organs, is about 1/10 or 10 times higher than the general population. A child with skin mastocytosis [urticaria pigmentosa, (UP)] and regressive autism is presented to illustrate the point. Allergic, infectious, neuroimmune and environmental triggers may activate mast cells to release vasoactive, inflammatory and neurotoxic molecules. These could disrupt the gut-blood-brain-barriers (BBB), and/or activate susceptibility genes, thus contributing to brain inflammation and ASD.
Keywords
References
| 1. | Johnson, CP, Myers, SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183–215. Google Scholar | Crossref | Medline | ISI |
| 2. | Gurney, JG, McPheeters, ML, Davis, MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med 2006; 160:825–30. Google Scholar | Crossref | Medline |
| 3. | Gerberding, J . Prevalence of autism spectrum disorder - Autism and developmental disabilities monitoring network, six sites, United States, 2000 and 2002. MMWR Morbidity and Mortality weekly report. 2007; 1–40. Google Scholar |
| 4. | Kogan, MD, Blumberg, SJ, Schieve, LA. Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among Children in the US, 2007. Pediatrics 2009; Epub. Google Scholar |
| 5. | Fombonne, E . Epidemiology of pervasive developmental disorders. Pediat Res 2009; 65:591–98. Google Scholar | Crossref | Medline |
| 6. | Horsfield, CI . The effect of compound 48/80 on the rat mast cell. J Pathol Bacteriol 1965; 90:599–605. Google Scholar | Crossref | Medline |
| 7. | Theoharides, TC, Doyle, R. Autism, gut-blood-brain barrier and mast cells. J Clin Psychopharmacol 2008; 28:479–83. Google Scholar | Crossref | Medline |
| 8. | Magalhaes, ES, Pinto-Mariz, F, Bastos-Pinto, S, Pontes, AT, Prado, EA, Deazevedo, LC. Immune allergic response in Asperger syndrome. J Neuroimmunol 2009; Epub. Google Scholar |
| 9. | Castells, M . Mast cell mediators in allergic inflammation and mastocytosis. Immunol. Allergy Clin North Am 2006; 26:465–85. Google Scholar | Crossref | Medline |
| 10. | Akin, C, Valent, P, Escribano, L. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep 2006; 6:282–88. Google Scholar | Crossref | Medline |
| 11. | Valent, P, Horny, HP, Escribano, L. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603–25. Google Scholar | Crossref | Medline | ISI |
| 12. | Castells, M, Austen, KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002; 127:147–52. Google Scholar | Crossref | Medline | ISI |
| 13. | Metcalfe, DD, Akin, C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001; 25:577–82. Google Scholar | Crossref | Medline | ISI |
| 14. | Bakkaloglu, B, Anlar, B, Anlar, FY, Oktem, F, Pehlivanturk, B, Unal, F, Ozbesler, C, Gokler, B. Atopic features in early childhood autism. Eur J Paediatr Neurol 2008; 12:476–9. Google Scholar | Crossref | Medline |
| 15. | Persico, AM, Sacco, R, Curatolo, P, Manzi, B, Lenti, C, Saccani, M, Militerni, R, Bravaccio, C, Elia, A. Isolation of principal components in autistic disorder symptomatology and their association with biological endophenotypes. Proc Society for Neuroscience, Washington DC 2008; Abstract #446.20. Google Scholar |
| 16. | Croen, LA, Grether, JK, Yoshida, CK, Odouli, R, Van de, WJ. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 2005; 159:151–7. Google Scholar | Crossref | Medline |
| 17. | Theoharides, TC, Kalogeromitros, D. The critical role of mast cell in allergy and inflammation. Ann NY Acad Sci 2006; 1088:78–99. Google Scholar | Crossref | Medline | ISI |
| 18. | Galli, SJ, Kalesnikoff, J, Grimbaldeston, MA, Piliponsky, AM, Williams, CM, Tsai, M. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23:749–86. Google Scholar | Crossref | Medline | ISI |
| 19. | Bachelet, I, Levi-Schaffer, F. Mast cells as effector cells: a co-stimulating question. Trends Immunol 2007; 28:360–5. Google Scholar | Crossref | Medline |
| 20. | Theoharides, TC, Cochrane, DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004; 146:1–12. Google Scholar | Crossref | Medline | ISI |
| 21. | Kim, KS, Wass, CA, Cross, AS, Opal, SM. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res 1992; 11:293–8. Google Scholar | Medline |
| 22. | de Boer, AG, Breimer, DD. Cytokines and blood-brain barrier permeability. Prog Brain Res 1998; 115:425–51. Google Scholar | Crossref | Medline |
| 23. | Abbott, NJ . Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000; 20:131–47. Google Scholar | Crossref | Medline | ISI |
| 24. | Chez, MG, Dowling, T, Patel, PB, Khanna, P, Kominsky, M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007; 36:361–5. Google Scholar | Crossref | Medline |
| 25. | Li, X, Chauhan, A, Sheikh, AM, Patil, S, Chauhan, V, Li, XM, Ji, L, Brown, T, Malik, M. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009; 207:111–16. Google Scholar | Crossref | Medline | ISI |
| 26. | Smith, SE, Li, J, Garbett, K, Mimics, K, Patterson, PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007; 27:10695–702. Google Scholar | Crossref | Medline | ISI |
| 27. | Theoharides, TC, Boucher, W, Spear, K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002; 128:344–50. Google Scholar | Crossref | Medline | ISI |
| 28. | Theoharides, TC, Kempuraj, D, Tagen, M, Conti, P, Kalogeromitros, D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007; 217:65–78. Google Scholar | Crossref | Medline | ISI |
| 29. | Cao, J, Papadopoulou, N, Kempuraj, D, Boucher, WS, Sugimoto, K, Cetrulo, CL, Theoharides, TC. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005; 174:7665–75. Google Scholar | Crossref | Medline | ISI |
| 30. | Kandere-Grzybowska, K, Letourneau, R, Kempuraj, D, Donelan, J, Poplawski, S, Boucher, W, Athanassiou, A, Theoharides, TC. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 2003; 171:4830–6. Google Scholar | Crossref | Medline | ISI |
| 31. | Vargas, DL, Nascimbene, C, Krishnan, C, Zimmerman, AW, Pardo, CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57:67–81. Google Scholar | Crossref | Medline | ISI |
| 32. | Conti, P, Pang, X, Boucher, W, Letourneau, R, Reale, M, Barbacane, RC, Thibault, J, Theoharides, TC. Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997; 89:4120–4127. Google Scholar | Crossref | Medline |
| 33. | Ashwood, P, Enstrom, A, Krakowiak, P, Hertz-Picciotto, I, Hansen, RL, Croen, LA, Ozonoff, S, Pessah, IN, de Water, JV. Decreased transforming growth factor betal in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol. 8-30-2008; 204:149–53. Google Scholar | Crossref | Medline |
| 34. | Gebhardt, T, Lorentz, A, Detmer, F, Trautwein, C, Bektas, H, Manns, MP, Bischoff, SC. Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1. Gut 2005; 54:928–34. Google Scholar | Crossref | Medline |
| 35. | Vojdani, A, Campbell, AW, Anyanwu, E, Kashanian, A, Bock, K, Vojdani, E. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol. 2002; 129:168–77. Google Scholar | Crossref | Medline |
| 36. | Cabalnit, M, Willis, S, Goines, P, Ashwood, P, Van de Water, J. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann NY Acad Sci 2007; 1107:92–103. Google Scholar | Crossref | Medline |
| 37. | Singer, HS, Morris, CM, Williams, PN, Yoon, DY, Hong, JJ, Zimmerman, AW. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol 2006; 178(1–2): 149–155. Google Scholar | Crossref | Medline |
| 38. | Zimmerman, AW, Connors, SL, Matteson, KJ, Lee, LC, Singer, HS, Castaneda, JA, Pearce, DA. Maternal antibrain antibodies in autism. Brain Behav.Immun. 2007; 21:351–57. Google Scholar | Crossref | Medline |
| 39. | Wills, S, Cabanlit, M, Bennett, J, Ashwood, P, Amaral, DG, Van de Water, J. Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders. Brain Behav. Immun. 7-30-2008; 23:64–74. Google Scholar | Crossref | Medline |
| 40. | Esposito, P, Chandler, N, Kandere-Grzybowska, K, Basu, S, Jacobson, S, Connolly, R, Tutor, D, Theoharides, TC. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002; 303:1061–6. Google Scholar | Crossref | Medline | ISI |
| 41. | Theoharides, TC, Konstantinidou, A. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 2007; 12:1615–28. Google Scholar | Crossref | Medline | ISI |
| 42. | Theoharides, TC, Letourneau, R, Patra, P, Hesse, L, Pang, X, Boucher, W, Mompoint, C, Harrington, B. Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Dig Dis Sci 1999; 44:87S–93S. Google Scholar | Crossref | Medline |
| 43. | Wallon, C, Yang, P, Keita, AV, Ericson, AC, McKay, DM, Sherman, PM, Perdue, MH, Soderholm, JD. Corticotropin releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008; 57:50–58. Google Scholar | Crossref | Medline |
| 44. | Castellani, ML, Conti, CM, Kempuraj, DJ. Autism and immunity: revisited study. Int J Immunopathol and Pharmacol 2009; 22:15–19. Google Scholar | SAGE Journals | ISI |
| 45. | Theoharides, TC, Doyle, R, Francis, K, Conti, P, Kalogeromitros, D. Novel therapeutic targets for autism. Trends Pharmacol Sci 2008; 29:375–82. Google Scholar | Crossref | Medline |
